Protein vaccines for T cell immunity are not being prioritized because of poor immunogenicity. To overcome this hurdle, proteins are being targeted to maturing dendritic cells (DCs) within monoclonal antibodies (mAbs) to DC receptors. To extend the concept to humans, we immunized human Ig-expressing mice with human DEC205 (hDEC205) extracellular domain. 3D6 and 3G9 mAbs were selected for high affinity binding to hDEC205. Also CD11c promoter hDEC205 transgenic mice were generated, and 3G9 selectively targeted to DCs in these animals. When mAb heavy chain was engineered to express HIV Gag p24, the fusion mAb induced IFN-γ and IL-2 producing CD4 + T cells in hDEC205 transgenic mice if poly IC was coadministered as adjuvant. The T cell response was broad recognizing at least 3 Gag peptides and high titers of anti-human IgG antibody were made. Anti-hDEC205 also improved cross presentation of Gag to primed CD8 + T cells from HIV infected individuals. In all tests, 3D6 and 3G9 targeting greatly enhanced immunization relative to nonbinding control mAb. These results provide preclinical evidence that in vivo hDEC205 targeting increases the efficiency with which proteins elicit specific immunity, setting the stage for proof of concept studies of these new protein vaccines in human subjects.
Introduction
Protein vaccines offer potential advantages with respect to ease and low costs of production, and ability to be administered repeatedly. Yet protein vaccines characteristically suffer from poor immunogenicity for the Th1 type of T cell mediated immunity that should help to resist global infectious diseases and cancers. The requirements for immunization are now better understood, particularly the importance of antigen delivery to dendritic cells (DCs) to achieve antigen presentation in vivo as well as DC maturation to differentiate the cells to overcome their normal role in inducing tolerance by different mechanisms [1] [2] [3] . To meet these DC requirements, it is logical to explore several receptors on DCs to improve antigen uptake and presentation in vivo, as well as several adjuvants that guide DC function (reviewed in 4, 5 ).
DEC205/CD205 is a member of the multilectin family of C-type lectins expressed by mammalian cells 6 . This family, which include the mannose receptor CD206 and the phospholipase A2 receptor, have 8-10 external contiguous lectin domains and mediate adsorptive endocytosis 7 . Amongst leukocytes, DEC205 is expressed at highest levels by dendritic cells (DCs) within the T cell areas of lymphoid tissues, which are the sites for the generation of immunity and tolerance. Although DCs are known to express many potential receptors to enhance antigen uptake and processing, DEC205 is currently the only receptor that has been visualized on most DCs in the T cell areas of human lymphoid organs 8 .
Proteins can be targeted selectively to mouse DCs in vivo when incorporated into a monoclonal antibody (mAb) specific for DEC205 1, 2 . This targeting increases the efficiency of antigen presentation on MHC class I and II molecules ~100 fold 3,9-12 as well as strong and protective T cell immunity 10 . With synthetic double stranded RNA as the only adjuvant, DEC205-targeting leads to Th1 immunity that is also durable, lasting for several months in mice 13 . The improved cell mediated immunity with poly IC as adjuvant is due to the high levels of type I interferon induced by this agonist through MDA5 and TLR3 pattern recognition receptors. Specifically, the maturation of DCs to become immunostimulatory requires their expression of type I interferon receptors 14 .
To extend the concept of protein targeting to DCs to human therapeutics, a series
For personal use only. on April 30, 2017. by guest www.bloodjournal.org From of human IgG mAbs to human DEC205 (hDEC205) were produced from human immunoglobulin transgenic mice that lack mouse immunoglobulin genes but carry the human Ig locus 15 . While these mAbs also react with DEC205 in rhesus macaques, the latter are expensive to explore many variables that are needed to move this vaccine strategy into proof of concept studies in humans. Therefore we generated transgenic (Tg) mice expressing the hDEC205 receptor on DCs. We will describe the capacity of human antihDEC205-HIV Gag p24 fusion mAb to enhance humoral and cellular immunity in vivo when poly IC adjuvant is coadministered.
Methods

Cells
Chinese hamster ovary (CHO) cells were cultured in DMEM (GIBCO Invitrogen, #11995) 5-10 % FBS (Sigma) or 5 % Ultra-Low IgG FBS supplemented with 2-mercaptoethanol, Antibiotic-Antimycotic, and Non-Essential Amino Acids (all from GIBCO Invitrogen).
Human monocyte-derived DCs (MoDCs) were generated from normal blood monocytes purchased as buffy coats from the New York Blood Center, as described 16 . Briefly, CD14 + cells were isolated using anti-CD14 beads (Miltenyi Biotec) and cultured 6 days in RPMI 1640 (GIBCO Invitrogen) with 5 % human serum (Gemini Bio-Products), IL-4 (R&D Systems; 10 ng/ml) and GM-CSF (Immunex; 100 IU/ml). To mature MoDCs, LPS (100 ng/ml) was added during the last 24 hrs.
Expression of full length human DEC205 and its external region
A synthetic open reading frame (ORF) for full-length hDEC205 with a V5 epitope tag, and stable CHO cells expressing hDEC205 (CHO/hDEC205 cells), were described 17 . In brief, a full-length hDEC205 ORF was amplified by PCR from a human thymic cDNA library (Clontech), followed by cloning and sequencing. To detect expression of full-length hDEC205 protein, the signal peptide was replaced with a mouse IgG signal peptide and a V5 epitope tag (V5-tagged hDEC205; GenBank accession #AY682091). This synthetic hDEC205 ORF was inserted into pCMV expression vector, transfected, and stably
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A synthetic DNA for hDEC205 extracellular domain was generated similarly, modified with V5-tagged mouse IgG signal peptide, and fused in-frame with human IgG1 (hIgG1) Fc domain amplified from human genomic DNA. The V5.hDEC205/hIgG1Fc construct (GenBank accession #DQ407610), was inserted into pCMV expression vector, transfected, stably expressed as CHO/V5.hDEC205/hIgG1Fc cells, and the culture supernatant used to purify V5.hDEC205/hIgG1Fc fusion protein by affinity to Protein A Sepharose™ (GE Healthcare, Piscataway, NJ) as described 18 .
Antibodies
Murinized NLDC145 mAb (mNLDC145, the original V regions from rat anti-mDEC205 mAb modified to express mouse kappa and IgG1 constant domains) and hybrid mAbs fused with antigens were described 1 . was purchased from Invitrogen. PE-conjugated anti-human-IgG was purchased from Jackson ImmunoResearch. FITC-anti-CD3, FITC-anti-B220, PerCP-anti-CD8, APC-anti-CD4, and APC-anti-CD11c were from BD Biosciences Pharmingen.
Generation of CD11c promoter-human DEC205 Tg mice
CD11c promoter-hDEC205 (CD11c-hDEC205) Tg mice were generated in the C57BL/6 strain using standard microinjection techniques. Briefly, hDEC205 cDNA was cloned into a synthetic CD11c promoter (GenBank Accession #DQ658851). The construct was linearized by digestion with restriction enzymes AatII and AscI, purified, and injected into fertilized pronuclei of C57BL/6 mice. Transgene positive mice were mated with C57BL/6.
Six founders were established and confirmed for germ-line transmission by PCR genotyping of tail DNA. The DEC205F 5'-TGGAAGAGACATGGAGAAACCT-3' and association and dissociation kinetics were followed for ~300 to 600 sec in each case.
Corresponding controls were conducted using an unrelated protein for "background" subtraction. A single injection of 18 mM NaOH for 17 sec at 35 µl/min was used as the regeneration conditions throughout the study. Biacore's kinetics wizard was used to derive kinetic parameters from the concentration series of analyte diluted in HBS-NP running buffer. Association and dissociation curves were fitted to a 1:1 Langmuir binding model using Biacore TM kinetics wizard software according to Biacore guidelines. To map the subdomain containing the epitope bound by mAb 3G9, a series of deletion constructs for hDEC205 extracellular domain were generated with a FLAG-tag sequence, i.e. CR/FN (GenBank accession #GU270871), CRD1/2 (accession #GU270872), CRD3/4 (accession #GU270873), CRD5/6 (accession #GU270874), CRD7/8 (accession #GU270875), CRD9/10 (accession #GU270876). Each construct was cloned into the pCMV vector and transiently expressed into 293T cells using Lipofectamine™ 2000 reagent (Invitrogen). Western blotting were done on transfectant cell lysates on 12 % SDS-PAGE using mAbs 3G9 and L5 (anti-FLAG) as described above.
Western blot analysis and epitope mapping
Immunohistochemical analysis of DEC205 expression
Spleen and lymph nodes from CD11c-hDEC205 Tg mice were harvested and frozen in To assess proliferation of primed T cells, bulk splenocytes were labeled with CFSE (10 7 cells/ml, 1 μM, 10 min, 37°C; Invitrogen) and cultured with anti-CD28 and either HIV Gag p24, nonreactive peptide mix or anti-CD3 (0.1 μg/ml; positive control) in 96-well, round-bottom plates. After 3 days, samples were restimulated 6 hrs with p24 peptides and
For personal use only. on April 30, 2017. by guest www.bloodjournal.org From anti-CD28, adding Brefeldin A (10 μg/ml) for the last 5 hrs. Cells were stained with PerCP-anti-CD3 and PE-anti-CD4 as above, permeabilized, stained with APC-anti-IFN-γ mAb for 15 min, and 40,000 CD3 + events acquired on BD FACSCalibur.
Humoral immunity after HIV Gag p24 immunization of CD11c-hDEC205 Tg mice
To assess B cell immunity, groups of 3 CD11c-hDEC205 Tg mice were injected i.p. with >0.1 was recorded as the titer. Antibody titer data were plotted on log scales.
Cross presentation of Gag to HIV primed human CD8 + T cells
PBMCs from HIV-infected donors were labeled with 1 μM CFSE and 10 6 cells plated in 96-deep well plates in 500 μl of RPMI with 5 % human serum. PBMCs were cultured 7d with no Gag antigen (negative control) or with HIV Gag peptides at 2 μg/ml or MG38.2-Gag p24, 3D6-p24, 3G9-p24 and control Ig-p24 at 1 μg/ml. To directly assess the function of DCs in presenting the Gag fusion mAbs, we used MoDCs in parallel to the PBMC assay above. Immature DCs at d5 of monocyte culture in GM-CSF and IL-4 were collected and pulsed overnight with medium, p24 peptides (2 μg/ml), or MG38.2-p24, 3D6-p24, 3G9-p24 and control Ig-p24 at 1 μg/ml. The antigen-pulsed MoDCs were matured by adding γ-irradiated CD40L-expressing cells (kindly provided by J. Banchereau, Dallas, TX) at a ratio of 1:5 (CD40L:DC) for 48 hrs. CD40 ligation enhances cross presentation by DCs 22 . Syngeneic CD14 -cells were thawed, rested for 2 hrs at 37 ºC prior to CFSE labeling, plated in 48-well plates at 1.5-2×10 6 /ml and cultured 6d with the antigen-pulsed mature MoDCs at a DC:T ratio 1:30. After 6-7 days of culture, all samples were restimulated 8 hrs -/+ p24 peptides (2 μg/ml) with 0.5 μg/ml of anti-CD28 and CD49d
(clones L293 and L25; BD Biosciences). Brefeldin A at 10 μg/ml was added for the last 6hrs. The cells were fixed, permeabilized and stained with perCP-anti-CD3, APC-anti-CD8, and PE-anti-IFN-γ or its respective isotype control (all from BD Bioscience). Cells were analyzed with a BD FACSCalibur, collecting 50,000-100,000 high CD3 + events.
All human subject experiments were approved by The Rockefeller University IRB.
Results
Production of hDEC205/hIgG1Fc fusion protein
To express hDEC205, cDNAs encoding full-length DEC205 proteins from human and mouse were cloned by PCR based on published sequences 6, 19 . A V5 epitope tag was inserted into the N-terminus to detect expression of recombinant hDEC205 protein or transgene. The cDNAs of V5-tagged hDEC205 (GenBank accession #AY682091) and C57BL/6 mDEC205 (GenBank accession #AF395445) were used to generate stable CHO cells expressing cell surface DEC205. To prepare a secreted form of DEC205, the fulllength extracellular domain of hDEC205 cDNA was fused to a human IgG1 Fc cassette (V5.hDEC205/hIgG1Fc; GenBank accession #DQ407610), transfected and stably expressed in CHO cells ( Figure 1A , left) to produce V5.hDEC205/hIgG1Fc protein of 90 % or better purity after Protein A ( Figure 1A , right). This protein was used to prepare mAbs.
Generation of human anti-human DEC205/CD205 monoclonal antibodies
Human Ig transgenic mice 15 were used to generate human anti-hDEC205 mAbs by Figure 1D ), verifying that the mAb detected the appropriate antigen when expressed on the cell surface ( Figures 1B-C) and by immunoblotting ( Figure 1D ). When blotting was used to determine the subdomain of hDEC205 protein reactive to 3G9 the epitope was in carbohydrate recognition domains (CRD) 1 and 2 (CRD1/2; Figure 1E ). As a control, we used either a nonbinding human IgG1 or 3G9 mAb with mutated complementarity determining region (CDR) sequences.
The new human anti-hDEC205 mAbs were then tested for reactivity with hDEC205 in vivo.
Generation of hDEC205 Tg mice
For personal use only. on April 30, 2017. by guest www.bloodjournal.
org From
To establish the in vivo targeting activity of human anti-hDEC205 mAbs, we generated transgenic mice expressing hDEC205 in mouse DCs. To do so, we used the promoter of the CD11c integrin α subunit, which is expressed at high levels on most DC subsets in mice.
Full-length hDEC205 cDNA linked to a previously described 5.8-kb fragment of mouse CD11c promoter 23 (CD11c-hDEC205; Figure 2A ) was integrated into the genome of C57BL/6 mice. Because the sequences of human and mouse DEC205 cDNAs are highly homologous, a set of PCR primers was designed to discriminate hDEC205 cDNA transgene from the mDEC205 gene, which contains introns ( Figure 2B ). Using this primer pair, we identified several founders expressing the hDEC205 transgene through germ-line transmission to the next generation ( Figure 2C ). Because 3G9 mAb showed the strongest binding to hDEC205 in FACS and Western blot analyses ( Figures 1B-E) , we used 3G9 to detect hDEC205 in tissues of the founder lines ( Figure 2C ). In the initial screen by FACS, the #49 line exhibited the highest expression of hDEC205 in spleen and lymph nodes (data not shown). These results were confirmed by immunolabeling of tissue sections, e.g., in lymph nodes of hDEC205 Tg #49 mice but not wild type mice, hDEC205 was localized to dendritic profiles in the T cell areas where DCs typically reside ( Figure 2D ).
To confirm hDEC205 expression on DCs from CD11c-hDEC205 Tg #49 mice, lymphoid cells were surface stained with 3G9 mAb. In spleen, CD8 + and CD8 -classical DCs (cDCs) expressed hDEC205 but plasmacytoid DCs (PDCs) did not ( Figure 2E ), while in lymph nodes, both cDCs and migratory DCs selectively expressed hDEC205 ( Figure 2F ).
CD11c-hDEC205 Tg #49 mice were chosen to test anti-hDEC205 mAbs for DC targeting.
Targeting of 3G9 mAb to DCs in vivo
To assess targeting of 3G9 mAb to DCs in vivo, 30 μg of Alexa 647-labeled 3G9 or control mAb was injected i.p. into wild type and CD11c-hDEC205 Tg mice. Neither of the injected mAbs was detectable in wild type mice, but in hDEC205 Tg mice, the injected 3G9 selectively labeled splenic cDCs while the control human IgG1 did not label any targets ( Figure 3 ). Thus 3G9 mAb targets to hDEC205 on DCs in vivo.
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Production of anti-hDEC205-p24 fusion mAbs
To evaluate the capacity of hDEC205 receptor on DCs to process and present antigens, 3D6 and 3G9 cDNAs were cloned and engineered to generate hybrid mAbs fused with HIV Gag p24 ( Figure 4A) . A control human IgG1 mAb Gag p24 fusion mAb was also generated by mutation of 3G9 parental CDR sequences. Following expression from mammalian cells and purification by protein A, the integrity and specificity of the Gag p24 fusion mAbs were confirmed by Coomassie stains, Western blots ( Figure 4B) , and FACS analyses with CHO/hDEC205 cells ( Figure 4C ). Next, we stained normal human spleen sections with 3G9-p24 fusion mAb. 3G9-p24 and MG38.2, a mouse anti-hDEC205, colabeled hDEC205 + DCs in T areas of human spleen ( Figure 4D ). Therefore, the human antihDEC205-HIV Gag p24 fusion mAb vaccines were ready for testing in mice.
Antigens targeted to hDEC205 are efficiently presented to CD4 + T cells in vivo
The HIV Gag p24-conjugated anti-hDEC205 fusion mAbs with adjuvant induced high frequencies of IFN-γ (and IL-2; data not shown) producing CD4 + T cells in hDEC205 Tg mice compared to control Ig-p24 immunization ( Figure 5A ). Pools 1 and 4 from the Gag peptide library were recognized by the CD4 + T cells ( Figure 5A ), which is in accordance with our previous immunizations with anti-mDEC205 Gag mAb 10 . In 3 experiments of the primary response to fusion mAb with poly IC and anti-CD40 as adjuvant, 3G9-p24 induced significantly more IFN-γ (and IL-2; data not shown) producing CD4 + T cells than 3D6-p24 and many more T cells relative to nontargeted control Ig-p24 mAb ( Figure 5A ).
To extend the study to an adjuvant with a good safety profile in human subjects, we used poly ICLC only to prime and boost mice one month apart with 3G9-HIV Gag p24, and 3G9-SIV Gag p27. The combination of targeted vaccine plus poly ICLC was immunogenic in hDEC205 Tg mice (figure 5B). We also immunized with 3G9-SIV Gag p41 to test if epitopes from both SIV Gag p17 and SIV Gag p27 regions were immunogenic, and this was the case ( Figure 5C ). To evaluate the quality of the T cell response, we
showed that the T cells were capable of antigen-specific proliferative activity ( Figure 5D ).
Thus high frequencies of CD4 + T cells with potentially valuable properties such as breadth
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Induction of humoral responses to anti-hDEC205 antibodies in vivo
To examine humoral responses in hDEC205 Tg mice, 10 μ g of 3D6, 3G9, or control human IgG1 mAbs were injected i.p. with adjuvant. One immunization of hDEC205 Tg mice with anti-hDEC205 mAbs 3D6 and 3G9 was sufficient to induce high IgG antibodies against human IgG1 (Figure 6 ). These antibodies against human anti-hDEC205 mAbs included a spectrum of all IgG subclasses, i.e. IgG1, IgG2b, IgG2c, and IgG3. There was no significant difference in total IgG titers between hDEC205 Tg mice immunized with 3D6 and 3G9 ( Figure 6A) ; however, the mice immunized with 3D6 had slightly higher IgG2c and IgG3 titers than those immunized with 3G9 ( Figures 6C, 6E ). High antibody titers against anti-hDEC205 mAbs were induced with an additional round of immunization in the absence of adjuvant (Figure 6 ). In the same experiment, control human IgG1 mAb generated no detectable humoral IgG responses in hDEC205 Tg mice (Figure 6 ), indicating the greatly enhanced humoral responses to anti-3D6 and anti-3G9 mAb targeting.
Cross presentation of human anti-hDEC205 HIV Gag to Gag primed T cells
To assess the capacity of the 3D6 and 3G9 mAbs to mediate cross presentation, we studied HIV-primed CD8 + T cells from HIV infected individuals as described 11 , since we were unable to prime large numbers of CD8 + T cells to HIV Gag in hDEC205 Tg mice in the C57BL/6 background. We compared the human-Gag p24 fusion mAbs to mouse MG38.2
anti-hDEC205-p24 and nonbinding control Ig-p24. Either whole PBMCs ( Figure 7A ) or mixtures of MoDC and T cells ( Figure 7B ) were used as described 11 . Anti-hDEC205 mAbs at just 1 μg/ml induced T cell proliferation and IFN-γ production from primed CD8 + T cells, comparably to cells expanded with a pool of fifty peptides spanning the Gag p24 sequence ( Figure 7 ). Thus the human anti-hDEC205 mAbs mediate cross presentation.
Discussion
Protein vaccines offer considerable potential relative to vector delivered vaccines in terms
For personal use only. on April 30, 2017. by guest www.bloodjournal.org From of reduced expense of production, ease of transport and storage, and capacity to repeatedly immunize without the obstacle of vector immunity. To render protein vaccines immunogenic, we have previously shown the value of targeting to receptors on DCs along with coadministration of adjuvants that render DCs immunostimulatory. In our studies, we have emphasized the DEC205 receptor for targeting, and poly IC as adjuvant.
To bring this potentially protective strategy into the clinic, it would help to have fully human anti-hDEC205 fusion mAbs. Human mAbs to hDEC205 proved feasible to produce, using human DEC205 extracellular domain to immunize mice carrying human not mouse Ig genes. We selected two mAbs, 3G9 and 3D6, for study because they both bound to human and rhesus DEC205 at high affinity. To carry out in vivo immunization experiments, we also developed a transgenic mouse expressing full-length hDEC205 in We then found that these transgenic mice developed strong CD4 + T cell responses to hDEC205 targeted HIV and SIV Gag proteins, but not control Ig targeted Gag. The T cell responses showed two valuable features, breadth or capacity to recognize several different Gag peptides, and proliferative capacity. In prior research 13 , we found that the T cell responses to DEC205-targeted antigen in mice are of the Th1 and not Th2 or Th17 types. We have been verifying this in ongoing studies in rhesus macaques where we used the 3G9-HIV gag p24 fusion mAb along with poly IC to immunize nonhuman primates.
However, Gag-specific CD8 + T cells were not detected in our immunized C57BL/6 mice, which are not known to present HIV Gag on MHC class I 10 . To verify that the new antihDEC205 mAbs could enhance cross presentation, we carried out experiments with CD8 + T cells from HIV infected individuals. We had shown previously that mouse anti-human DEC-targeted gag p24 was reliably cross presented to human CD8 + T cells. Here we verified that human 3G9 and 3D6 anti-DEC205 greatly enhanced cross presentation relative
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to control fusion mAbs, and as active as pools of Gag peptides to load antigen into DCs.
We did not assess the behaviour of regulatory Foxp3 + T cells in the current paper because in a prior study we showed that the use of poly IC as an adjuvant blocks the induction of Treg by DEC205 targeted antigen 24 .
To assess B cell responses, we followed antibody formation to the human IgG following 3G9 and 3D6 immunization. The new targeting mAbs, but not nontargeting control, elicited high titres of anti-human IgG. These B and T cell findings propend feasibility to use protein vaccines to induce immunity to clinically relevant antigens as long as these are delivered efficiently to DCs together with appropriate adjuvants. Since DEC205 targeting enhances the immunogenicity of protein vaccines, which offer potential advantages with respect to ease and low costs of production, and ability to be administered repeatedly, we propose to test human DEC targeted protein antigens as stand alone vaccines and in combination with other approaches such as recombinant viral vectors.
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